Efficacy of meningococcal vaccine and barriers to vaccination

JAMA

Volumn 279, Issue 6, 1998, Pages 435-439

  Rosenstein, Nancy ^a,d   Levine, Orin ^a   Taylor, Jeffery P ^c   Evans, Deborah ^c   Plikaytis, Brian D ^b   Wenger, Jay D ^a   Perkins, Bradley A ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^c TEXAS DEPARTMENT OF STATE HEALTH SERVICES   (United States)

^d NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; EPIDEMIC MENINGITIS; HUMAN; IMMUNIZATION; INFECTION CONTROL; INFECTION RISK; NEISSERIA MENINGITIDIS; PRIORITY JOURNAL; RISK FACTOR; SEROCONVERSION; TARGET CELL; VACCINATION;

EID: 0032506993     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.279.6.435     Document Type: Article

References (27)

1. Centers for Disease Control and Prevention. Surveillance for diabetes mellitus - United States, 1980-1989, and laboratory-based surveillance for meningococcal disease in selected areas - United States, 1989-1991. MMWR Morb Mortal Wkly Rep. 1993;42(SS-2):21-30.
2. Jackson LA, Schuchat A, Reeves MW, Wenger JD. Serogroup C meningococcal outbreaks in the United States: an emerging threat. JAMA. 1995;73:383-389.
3. Centers for Disease Control and Prevention. Control and prevention of meningococcal disease and control and prevention of serogroup C meningoeoccal disease. MMWR Morb Mortal Wkly Rep. 1997;46:1-21.
4. Selander RK, Caugant DA, Ochman H, et al. Methods of multilocus enzyme electrophoresis for bacterial population genetics and systematics. Appl Environ Microbiol. 1986;51:873-884.
5. Caugant DA, Mocca LF, Frasch CE, et al. Genetic structure of Neisseria meningitidis populations in relation to serogroup, serotype, and outer Membrane protein pattern. J Bacteriol. 1987;169: 2781-2792.
6. Woods TC, Helsel LO, Swaminathan B. Characterization of Neisseria meningitidis serogroup C by multilocus enzyme electrophoresis and ribosomal DNA restriction profiles. J Clin Microbiol. 1992;30:132-137.
7. Orenstein WA, Bernier RH, Hinman AR. Assessing vaccine efficacy in the field. Epidemiol Rev. 1988; 10:212-241.
8. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73: 13-22.
9. Gold R, Lepow ML, Goldschneider I, et al. Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. J Clin Invest. 1975; 56:1536-1547.
10. Ashton FE, Ryan JA, Borczyk A, et al. Emergence of a virulent clone of Neisseria meningitidis serotype 2a that is associated with meningococcal group C disease in Canada. J Clin Microbiol. 1991;29: 2489-2492.
11. Fischer M, Hedberg K, Cardosi P, et al. Tobacco smoke as a risk factor for meningococcal disease. Pediatr Infect Dis J. 1997;16:979-983.
12. Whitney CG, Dondoc N, Enktuja B, et al. Efficacy of Neisseria meningitidis serogroup A/C polysaccharide vaccine among children in Mongolia. In: Programs and abstracts of the 10th International Pathogenic Neisseria Conference; September 8-13, 1996; Baltimore, Md.
13. Artenstein MS, Gold R, Zimmerly JG, et al. Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med. 1970;282:417-420.
14. Gold R, Artenstein MS. Meningococcal infections, 2: field trial of group C meningococcal polysaccharide vaccine in 1969-70. Bull World Health Organ. 1971; 45:279-282.
15. Biselli R, Fattorossi A, Matricardi PM, et al. Dramatic reduction of meningococcal meningitis among military recruits in Italy after introduction of specific vaccination. Vaccine. 1993;11:578-581.
16. Taunay AE, Feldman RA, Bactos CO, et al. Assessment of the protection conferred by anti-group C meningococcal polysaccharide vaccine to 6 to 36 month-old children. Rev Inst Adolfo Lutz. 1978;38:77-82.
17. De Wals P, Dionne M, Douville-Fradet M, et al. Impact of a mass immunization campaign against serogroup C meningococcus in the Province of Quebec, Canada. Bull World Health Organ. 1996;74:407-411.
18. Adams WG, Deaver KA, Cochi SL, et al. Decline of childhood Haemophilus influenzae type b disease in the Hib vaccine era. JAMA. 1993;269:221-226.
19. Gotschlich EC, Goldschneider I, Artenstein S. Human immunity to the meningococcus. J Exp Med. 1969;129:1385-1395.
20. Moore PS, Harrison LH, Telzak EE, et al. Group A meningococcal carriage in travelers returning from Saudi Arabia. JAMA. 1988;260:2686-2689.
21. Blakesbrough IS, Greenwood BM, Whittle HC, Bradley AK. Failure of meningococcal vaccination to stop the transmission of meningococci in Nigerian schoolboys. Ann Trop Med Parasitol. 1983;77:175-178.
22. Hassan-King MKA, Wall RA, Greenwood BM. Meningococcal carriage, meningococcal disease and vaccination. J Infect. 1988;16:55-59.
23. Imrey PB, Jackson LA, Ludwinski PH, et al. Outbreak of serogroup C meningococcal disease associated with campus bar patronage. Am J Epidemiol. 1996;143:624-630.
24. Le Saux N, Ashton F, Rahman M, et al. Carriage of Neisseria species in communities with different rates of meningococcal disease. Can J Infect Dis. 1992; 3:60-64.
25. Tappero JW, Reporter R, Wenger JD, et al. Meningococcal disease in Los Angeles County, California, and among men in the county jails. N Engl J Med. 1996;335:833-840.
26. Lieberman JM, Chiu SS, Wong VK, et al. Safety and immunogenicity of serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children. JAMA 1996;275:1499-1503.
27. Roberts CL, Roome A, Algert CS, et al. A meningococcal vaccination campaign on a university campus. Am J Public Health, 1996;86:1155-1158.